European Journal of Clinical Pharmacology

, Volume 69, Issue 7, pp 1375–1390

N-acetylcysteine for the prevention of non-contrast media agent-induced kidney injury: from preclinical data to clinical evidence

Authors

  • Hesamoddin Hosseinjani
    • Department of Clinical Pharmacy, Faculty of PharmacyTehran University of Medical Sciences
  • Azadeh Moghaddas
    • Department of Clinical Pharmacy, Faculty of PharmacyTehran University of Medical Sciences
    • Department of Clinical Pharmacy, Faculty of PharmacyTehran University of Medical Sciences
Review Article

DOI: 10.1007/s00228-013-1494-8

Cite this article as:
Hosseinjani, H., Moghaddas, A. & Khalili, H. Eur J Clin Pharmacol (2013) 69: 1375. doi:10.1007/s00228-013-1494-8

Abstract

Purpose

To review available evidence on the effectiveness of N-acetylcysteine (NAC) as a prophylactic agent in the prevention of non-contrast media agent-induced kidney injury.

Method

Data were collected by searching Scopus, PubMed, Medline, Science direct and Cochrane database systematic reviews. A total of 26 relevant experimental studies up to the date of publication were included in the review.

Results

Available evidence shows that NAC has the potential to exert significant protective or ameliorative effects against drug-induced kidney injury in experimental models. The possible suggested renoprotective mechanisms of NAC in different experimental settings were acting as an antioxidant by restoring the pool of intracellular reduced glutathione, scavenging of free radicals, and/or interacting with reactive oxygen species.

Conclusion

Whether the administration of NAC could be an effective protective clinical strategy to prevent drug-induced kidney injury or not is a question that remains to be answered in future clinical trials.

Keywords

N-acetylcysteine Drug-induced kidney injury Renoprotective mechanisms Ameliorative effects

Copyright information

© Springer-Verlag Berlin Heidelberg 2013